Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Lowering beta-amyloid levels in blood to treatment Alzheimer’s


Agents that alter blood levels of beta-amyloid protein in mouse models of Alzheimer’s disease represent a potential approach to treating the illness in humans that may be safer than the vaccine method of therapy, researchers report in a new study.

Beta-amyloid protein is a component of the amyloid plaques that accumulate in the brains of people with Alzheimer¡’s disease. Beta-amyloid is viewed by many researchers and clinicians as the underlying cause of the degeneration and dementia that characterize the illness. Alzheimer’s disease is a progressive, degenerative brain disease and the most common form of dementia. There is no cure. Approximately four million Americans have the disease and some 14 million are expected to have it by 2050 unless a cure or preventive treatment is found.

"Recent evidence suggests that this protein in the peripheral circulation outside the brain may contribute to its accumulation in the brain," says study co-author Karen Duff, PhD, of the Center for Dementia Research, Nathan Kline Institute/New York University. The study, funded by the National Institutes of Health and the Alzheimer’s Association, appears in the January 1 issue of The Journal of Neuroscience.

If Alzheimer’s disease can effectively be treated by agents that do not need to enter the brain, pharmaceutical companies may be able to develop targeted drugs that have few effects on the central nervous system, she adds. Previous animal studies suggested that one way to do this was through a vaccine that produced antibodies to amyloid. But Elan Corporation and American Home Products ended trials of their immune-based Alzheimer’s vaccine in February 2002 after 15 patients experienced swelling of the central nervous system.

"There’s good medical precedent seen in the treatment of coronary heart disease by administering agents that lower serum cholesterol levels," notes Bradley Hyman, MD, PhD, a neurologist at Massachusetts General Hospital in Boston. "This kind of parallel approach ¨C blocking beta-amyloid accumulation in the brain by binding it to an agent in the bloodstream ¨C represents an extremely viable line of research."

Other scientists, however, suggest the results of such studies be viewed with caution. "Having a substance that acts as a peripheral sink for brain beta-amyloid may simply be shifting the damage from the brain to the vasculature and body itself," says Gary Arendash, PhD, professor of biology and psychology at the University of South Florida. "This approach may trap a considerable amount of beta-amyloid in the cerebral blood vessels, weakening them and leading to cerebral hemorrhage."

In the new study, Duff, Dr. Yasuji Matsuoka and their colleagues injected the beta-amyloid binding agent gelsolin into the peripheral bloodstreams of 13 mice bred to develop Alzheimer’s disease. They also performed sham injections in 16 other mice with the same genetic background. Both groups received injections every two days for three weeks. Upon examination, the brains of mice receiving gelsolin had significantly less beta-amyloid protein than those in the other group. Use of gelsolin also resulted in a significant decrease in the number of brain plaques.

The scientists saw similar results when they used another beta-amyloid binding agent, ganglioside GM1.

"We do not advocate using these particular agents as treatments for Alzheimer’s disease in humans," Duff says. "Rather, we see this as an initial step in the development of compounds that act in this manner, and as proof-of-concept for a prophylactic approach that may be more flexible, more reliable and less likely to cause side effects in long-term administration paradigms than immunization-based therapies."

Duff and Matsuoka’s colleagues in this study include: Mariko Saito, Mitsuo Saito, John LaFrancois, Kate Gaynor, Vicki Olm, Lili Wang, Evelyn Casey, Yifan Lu, Chiharu Shiratori and Cynthia Lemere. Duff, Matsuoka and Lemere are members of the Society for Neuroscience, which publishes The Journal of Neuroscience. SfN is an organization of more than 31,000 basic scientists and clinicians who study the brain and nervous system. Duff can be reached at 845-398-5427; Matsuoka can be reached at

Phil Kibak | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

'Neighbor maps' reveal the genome's 3-D shape

27.10.2016 | Life Sciences

Gene therapy shows promise for treating Niemann-Pick disease type C1

27.10.2016 | Life Sciences

Solid progress in carbon capture

27.10.2016 | Power and Electrical Engineering

More VideoLinks >>>